These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
275 related articles for article (PubMed ID: 29689710)
1. ESR1 and PIK3CA mutational status in serum and plasma from metastatic breast cancer patients: A comparative study. Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Tomiguchi M; Sueta A; Iwase H Cancer Biomark; 2018; 22(2):345-350. PubMed ID: 29689710 [TBL] [Abstract][Full Text] [Related]
2. Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer. Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Tomiguchi M; Sueta A; Murakami K; Iwase H Mol Cancer; 2018 Feb; 17(1):67. PubMed ID: 29482551 [TBL] [Abstract][Full Text] [Related]
3. Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer. Shibayama T; Low SK; Ono M; Kobayashi T; Kobayashi K; Fukada I; Ito Y; Ueno T; Ohno S; Nakamura Y; Takahashi S Breast Cancer Res Treat; 2020 Apr; 180(2):331-341. PubMed ID: 32020432 [TBL] [Abstract][Full Text] [Related]
4. Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients. Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Inao T; Sueta A; Fujiwara S; Omoto Y; Iwase H Oncotarget; 2016 May; 7(22):32504-18. PubMed ID: 27102299 [TBL] [Abstract][Full Text] [Related]
5. Circulating Tumor DNA Profiling From Breast Cancer Screening Through to Metastatic Disease. Page K; Martinson LJ; Fernandez-Garcia D; Hills A; Gleason KLT; Gray MC; Rushton AJ; Nteliopoulos G; Hastings RK; Goddard K; Ions C; Parmar V; Primrose L; Openshaw MR; Guttery DS; Palmieri C; Ali S; Stebbing J; Coombes RC; Shaw JA JCO Precis Oncol; 2021; 5():. PubMed ID: 34849446 [TBL] [Abstract][Full Text] [Related]
6. Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer. Guttery DS; Page K; Hills A; Woodley L; Marchese SD; Rghebi B; Hastings RK; Luo J; Pringle JH; Stebbing J; Coombes RC; Ali S; Shaw JA Clin Chem; 2015 Jul; 61(7):974-82. PubMed ID: 25979954 [TBL] [Abstract][Full Text] [Related]
7. Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients. Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Sueta A; Tomiguchi M; Murakami K; Omoto Y; Iwase H BMC Cancer; 2017 Nov; 17(1):786. PubMed ID: 29166868 [TBL] [Abstract][Full Text] [Related]
8. Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer. Clatot F; Perdrix A; Beaussire L; Lequesne J; Lévy C; Emile G; Bubenheim M; Lacaille S; Calbrix C; Augusto L; Guillemet C; Alexandru C; Fontanilles M; Sefrioui D; Burel L; Guénot S; Richard D; Sarafan-Vasseur N; Di Fiore F Breast Cancer Res; 2020 May; 22(1):56. PubMed ID: 32466779 [TBL] [Abstract][Full Text] [Related]
9. Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer. Board RE; Wardley AM; Dixon JM; Armstrong AC; Howell S; Renshaw L; Donald E; Greystoke A; Ranson M; Hughes A; Dive C Breast Cancer Res Treat; 2010 Apr; 120(2):461-7. PubMed ID: 20107891 [TBL] [Abstract][Full Text] [Related]
10. PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy. Jacot W; Dalenc F; Lopez-Crapez E; Chaltiel L; Durigova A; Gros N; Lozano N; Lacaze JL; Pouderoux S; Gladieff L; Romieu G; Roché H; Filleron T; Lamy PJ Breast Cancer Res Treat; 2019 Oct; 177(3):659-667. PubMed ID: 31297647 [TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients. Beije N; Sieuwerts AM; Kraan J; Van NM; Onstenk W; Vitale SR; van der Vlugt-Daane M; Dirix LY; Brouwer A; Hamberg P; de Jongh FE; Jager A; Seynaeve CM; Jansen MPHM; Foekens JA; Martens JWM; Sleijfer S Mol Oncol; 2018 Jan; 12(1):48-57. PubMed ID: 29063679 [TBL] [Abstract][Full Text] [Related]
12. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1). Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563 [TBL] [Abstract][Full Text] [Related]
13. Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer. Chen TW; Hsiao W; Dai MS; Lin CH; Chang DY; Chen IC; Wang MY; Chang SH; Huang SM; Cheng AL; Wu KW; Tan KT; Lu YS Breast Cancer Res Treat; 2023 Oct; 201(3):377-385. PubMed ID: 37344660 [TBL] [Abstract][Full Text] [Related]
14. Highly sensitive detection of ESR1 mutations in cell-free DNA from patients with metastatic breast cancer using molecular barcode sequencing. Masunaga N; Kagara N; Motooka D; Nakamura S; Miyake T; Tanei T; Naoi Y; Shimoda M; Shimazu K; Kim SJ; Noguchi S Breast Cancer Res Treat; 2018 Jan; 167(1):49-58. PubMed ID: 28905136 [TBL] [Abstract][Full Text] [Related]
15. c-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive/HER2-negative metastatic breast cancer. Park J; Chang ES; Kim JY; Chelakkot C; Sung M; Song JY; Jung K; Lee JH; Choi JY; Kim NY; Lee H; Kang MR; Kwon MJ; Shin YK; Park YH; Choi YL Breast Cancer Res; 2024 Jan; 26(1):13. PubMed ID: 38238761 [TBL] [Abstract][Full Text] [Related]
16. Mutation Analysis of Cell-Free DNA and Single Circulating Tumor Cells in Metastatic Breast Cancer Patients with High Circulating Tumor Cell Counts. Shaw JA; Guttery DS; Hills A; Fernandez-Garcia D; Page K; Rosales BM; Goddard KS; Hastings RK; Luo J; Ogle O; Woodley L; Ali S; Stebbing J; Coombes RC Clin Cancer Res; 2017 Jan; 23(1):88-96. PubMed ID: 27334837 [TBL] [Abstract][Full Text] [Related]
17. Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR Moynahan ME; Chen D; He W; Sung P; Samoila A; You D; Bhatt T; Patel P; Ringeisen F; Hortobagyi GN; Baselga J; Chandarlapaty S Br J Cancer; 2017 Mar; 116(6):726-730. PubMed ID: 28183140 [TBL] [Abstract][Full Text] [Related]
18. Detection of Activating Estrogen Receptor Gene ( Paolillo C; Mu Z; Rossi G; Schiewer MJ; Nguyen T; Austin L; Capoluongo E; Knudsen K; Cristofanilli M; Fortina P Clin Cancer Res; 2017 Oct; 23(20):6086-6093. PubMed ID: 28679775 [No Abstract] [Full Text] [Related]
19. Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients. Wang P; Bahreini A; Gyanchandani R; Lucas PC; Hartmaier RJ; Watters RJ; Jonnalagadda AR; Trejo Bittar HE; Berg A; Hamilton RL; Kurland BF; Weiss KR; Mathew A; Leone JP; Davidson NE; Nikiforova MN; Brufsky AM; Ambros TF; Stern AM; Puhalla SL; Lee AV; Oesterreich S Clin Cancer Res; 2016 Mar; 22(5):1130-7. PubMed ID: 26500237 [TBL] [Abstract][Full Text] [Related]
20. Analysis of Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Tomiguchi M; Sueta A; Murakami K; Omoto Y; Iwase H Oncotarget; 2017 Aug; 8(32):52142-52155. PubMed ID: 28881720 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]